Monday 27 May 15:45-17:15
Late Breaking session on pharmacology of dyslipidemia
- Francois Mach, Switzerland
-
Alexandros Tselepis, Greece
Alexandros Tselepis
Ioannina, Greece
Professor of Biochemistry-Clinical Chemistry University of Ioannina, Greece
Director of the Atherothrombosis Research Centre of the University of Ioannina, GreeceAlexandros D. Tselepis was born in 1954 in Heraklion Crete, Greece. He has graduated in Pharmacy from the School of Pharmacy, University of Thessaloniki and in Medicine from the Medical School, University of Ioannina, Greece. He obtained his PhD in Clinical Biochemistry in 1986 from the University of Ioannina, Greece. His research studies continued with a Postdoctoral Fellowship (Fogarty, NIH) at the Pathology Department, University of Texas Health Science Center, San Antonio, TX, USA (1988–1989). After initial appointments as Assistant and Associate Professor, he took up his current position of Professor of Biochemistry–Clinical Chemistry in the University of Ioannina, in 2006. Professor Tselepis is also the Director of the Atherothrombosis Research Centre of the University of Ioannina.
Professor Tselepis’ main scientific interests are in the pathophysiology of Atherothrombosis. He has participated in several European Research Networks and he has obtained research grants from National, EU and Private Sources. He has more than 220 publications at international journals and more than 5,300 citations, whereas his current h-index is 39.
Professor Tselepis is Editor of the Hellenic Journal of Atherosclerosis, and member of the Editorial Boards of various international journals including Vascular Disease Prevention, American Journal of Biochemistry and Biotechnology, and Platelets. He is president of the Hellenic Atherosclerosis Society, president of the Institute for the Study and Education on Thrombosis and Antithrombotic Therapy, and a fellow of several national and international scientific societies including European Atherosclerosis Society (EAS), International Society on Thrombosis and Haemostasis (ISTH), European and Mediterranean League against Thrombotic Diseases (EMLTD).
Professor Tselepis has an over than 15 years experience in the organization of national congresses and international meetings, including the annual international meeting ALPIC (Advance Learning on Platelets and thrombosis International Cource) held under the auspicies of EMLTD and endorsed by the ISTH and the Meetings on Lipid, Lipoproteins and Hypolipidaemic Therapy (jointly organized by EAS, the Turkish Society of Cardiology and the Hellenic Atherosclerosis Society). Currently Prof Tselepis has taken on the organization of an EAS advanced course on FH in Athens.
LDL-C LOWERING AMONG PATIENTS WITH LDL-C ABOVE 4.9 MMOL/L AND FEATURES SUGGESTING A GENETIC VULNERABILITY TO CARDIOVASCULAR DISEASE: ANALYSES FROM THE 4S TRIAL
Antonio J Vallejo-Vaz, London, United Kingdom
METABOLOMIC CONSEQUENCES OF PCSK9 INHIBITION COMPARED WITH STATIN THERAPY
Peter Würz, Helsinki, Finland
INCLISIRAN DURABLY LOWERS LDL-C AND PCSK9 EXPRESSION IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: THE ORION-2 PILOT STUDY
Frederick Raal, Johannesburg, South Africa
SAFETY, TOLERABILITY AND LDL-C REDUCTION WITH A NOVEL ANTI-PCSK9 RECOMBINANT FUSION PROTEIN (LIB003): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY
Evan Stein, Chicago, USA
EFFICACY AND SAFETY OF BEMPEDOIC ACID + EZETIMIBE FIXED-DOSE COMBINATION IN PATIENTS AT HIGH CVD RISK AND WITH ELEVATED LDL-C RECEIVING MAXIMALLY TOLERATED STATIN THERAPY
Christy Ballantyne, Houston, USA
Tuesday 28 May 15:30-17:00
Late Breaking session on experimental atherosclerosis and genetics
- Geesje M. Dallinga-Thie, The Netherlands
- Bart Staels, France
FUNCTION AND MUTATION OF NETRIN-1 IN PREMATURE ATHEROSCLEROSIS
Caroline Bruikman, Amsterdam, The Netherlands
A HUMAN-LIKE COMPOSITION OF THE CIRCULATING BILE ACID POOL IMPACTS ON PLASMA LDL CHOLESTEROL IN MICE
Jan Freark De Boer, Groningen, The Netherlands
A COMMON VARIANT IN THE NLRP3 INFLAMMASOME LOCUS ASSOCIATES WITH MORTALITY
Winfried März, Mannheim, Germany
GENETICS OF HUMAN PLASMA LIPIDOME AND ITS LINK TO DISEASES SUSCEPTIBILITY
Rubina Tabassum, Helsinki, Finland
PREMATURE MORBIDITY AND MORTALITY AMONG DIAGNOSED AND POTENTIALLY UNDIAGNOSED FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN THE GENERAL POPULATION: AN OBSERVATIONAL STUDY OF OVER 1.7 MILLION HEALTH RECORDS
Kausik Ray
London, UK
Kausik Kumar Ray is currently Professor of Public Heath, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and European Atherosclerosis Society also serving on the EAS Consensus panel. Professor Ray has been the national lead investigator (SC or EC member) for several major medical trials, and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS. Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 59, an i10 of 123 and over 26,000 citations overall, including over 170 publications in journals including NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH and includes 68 countries, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.
